Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus

Pediatric Transplantation

Volumn 8, Issue 4, 2004, Pages 362-366

  Casas Melley, Adela T ^a   Falkenstein, Kathleen P ^a   Flynn, Louise M ^a   Ziegler, Valerie L ^a   Dunn, Stephen P ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Liver transplantation; Rejection; Renal insufficiency; Sirolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCINEURIN INHIBITOR; CREATININE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EPSTEIN BARR VIRUS; FEMALE; GLOMERULUS BASEMENT MEMBRANE; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD; MOUTH ULCER; NEPHROTOXICITY; NEUTROPENIA; PEDIATRIC SURGERY; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; SEIZURE; THROMBOCYTOPENIA; THRUSH; TREATMENT INDICATION; VIRUS INFECTION; WOUND INFECTION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MALE; NEUTROPENIA; ORAL ULCER; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 4043089144     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00193.x     Document Type: Article

References (12)

1. United Network of Organ Sharing (UNOS) published data 2003 (http://www.unos.org).
2. REICH D, ROTHSTEIN K, MANZARBEITIA C, MUNOZ S. Common medical diseases after transplantation. Semin Gastrointest Dis 1998: 9: 110-125.
3. GONWA TA, MORRIS CA, GOLDSTEIN RM, HUSBERG BS, KLINTMALM GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991: 51: 428-430.
4. GONWA TA, MAI ML, MELTON LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001: 72: 1934-1939.
5. MCDONALD AS. Management strategies for nephrotoxicity. Transplantation 2000: 69: S31-S36.
6. WIESNER R, RABKIN J, KLINTMALM G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001: 7: 442-450.
7. MURGIA MG, JORDAN S, KAHAN BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisilone-treated renal transplant patients. Kidney Int 1996: 49: 209-216.
8. KIMBALL PM, KERMAN RH, KAHAN BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991: 51: 486-490.
9. PAPPAS PA, WEPPLER D, PINNA AD, et al. Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 2000: 4: 45-49.
10. KAHAN BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194-202.
11. MCDONALD AS, Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of sirolimus/cyclosporine regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001: 71: 271-280.
12. DUNKELBERG JC, TROTTER JF, WACHS M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003: 9: 463-468.